AB0449 Sdai reduction at week 2 predict the sdai remission at week 24 when certolizumab pegol (CZP) was administered to patients with rheumatoid arthritis. (12th June 2018)

• Record Type: Journal Article
• Authors: Oryoji, K.; Mizuki, S.-I.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1387
• Page End: 1387
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.6353
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Certolizumab pegol (CZP) is approved for treatment of rheumatoid arthritis. Objectives: To explore the predictor of efficacy of certolizumab pegol (CZP) for MTX-IR patients with rheumatoid arthritis in our retrospective study. Methods: 50 patients who received CZP for rheumatoid arthritis of MTX-IR after 2013 were examined by losistic regression analysis using Age, sex, duration of disease, HAQ, TJC, SJC, gVAS, eVAS, CRP, SDAI, DAS 28-CRP, previous use of biologics, prednisolone use, ACPA, RF, the reduction rate of SDAI at week 2 to assess the predicting factor for SDAI remission at week 24. Results: As a factor capable of achieving SDAI remission at 24 weeks after CZP administration, SDAI reduction rate of 50% or more (n=28, p<0.001), females (p=0.01), the number of swollen joints (p=0.02) were extracted as significant factors. The odds ratio at which SDAI remission can be obtained at 24 weeks point is 15.4 (95% CI: 3.1–109.6) when the SDAI reduction rate at 2 weeks after the start of administration is 50% or more. SDAI remission rate at week 24 were 67% in SDAI reduction ≥50% at week 2 group and 22% in another. The continuation rate at week 24 in SDAI reduction ≥50% at week 2 is 93%. Conclusions: When SDAI decreased by 50% or more at 2 weeks after initiation of CZP administration SDAI remission was easy to obtain after 24 weeks, and continuation rate was also good. Disclosure of Interest: None declared